Delveinsight

Diabetic Gastroparesis Market Insights, Epidemiology and Market Forecast-2028

 

Albany, NY -- (SBWIRE) -- 08/01/2019 -- Diabetic Gastroparesis Market Insights, Epidemiology and Market Forecast-2028

1. Gastroparesis prevalence was 24.2 per 100,000 persons for both genders, where 9.6 per 100,000 is for men, and 37.8 per 100,000 is for women.
2. Gastroparesis higher prevalence was observed in women than in men.
3. Diabetic Gastroparesis total prevalent population in the 7 major markets was 23,526,461 in 2017.

DelveInsight launched a new report on Diabetic Gastroparesis Market Insights, Epidemiology and Market Forecast-2028

Key benefits

1. Diabetic Gastroparesis market report covers a descriptive overview and comprehensive insight of the Diabetic Gastroparesis epidemiology and Diabetic Gastroparesis market in the 7 MM (United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Diabetic Gastroparesis market report provides insights on the current and emerging therapies.
3. Diabetic Gastroparesis market report provides a global historical and forecasted market covering drug outreach in 7 MM.
4. Diabetic Gastroparesis market report offers an edge that will help in developing business strategies by understanding trends that shape and drive the Diabetic Gastroparesis market.

Request for sample pages

"Delayed gastric emptying is reported in one-third of diabetic patients with equal prevalence in type 1 and type 2 diabetes."

Treating the cause of gastroparesis (such as tightening up blood glucose control in diabetes) is generally the main step. The primary gastroparesis treatment goals in people with diabetes are to improve gastric emptying and to regain control of blood glucose levels. The specific therapeutic techniques used, depend upon several factors, including the severity of the disorder. Gastroparesis treatments include insulin (the affected individual is advised to take insulin more often), oral medications, dietary changes (change the eating habits to control the severity of gastroparesis symptoms), medications that stimulate gastric emptying (prokinetics) and, in severe cases, a feeding tube or intravenous feeding.
Several drugs are used for Gastroparesis treatment such as Metoclopramide (Reglan), which is a medication that stimulates stomach muscle contractions. It also helps reduce nausea and vomiting. Reglan Injection (metoclopramide hydrochloride, USP) is used for giving relief from Gastroparesis symptoms associated with acute and recurrent diabetic gastric stasis. Motilium (Domperidone) is another approved drug that is used for short-term treatment in adults for treating idiopathic or diabetic gastroparesis symptoms. Non-pharmacological interventions include liquid vitamin supplements (including optimal levels of vitamin D), discontinuation of smoking, and alcohol use, learning different techniques of deep relaxation, the use of acupuncture or acupoint stimulation will bring benefits.

The dynamics of Diabetic Gastroparesis market is expected to change in future owing to the improvement in the diagnosis methodologies raising awareness of the disease, incremental healthcare spending across the world and the launch of Diabetic Gastroparesis emerging therapies during the forecast period of 2018-2028 is expected.

Drugs covered
1. Relamorelin
2. Gimoti
And many others
The key players in Diabetic Gastroparesis market are:
1. Allergan
2. Evoke Pharma Inc
And many others

Table of contents

1. Report Introduction
2. Diabetic Gastroparesis Market Overview at a Glance
3. Diabetic Gastroparesis Disease Background and Overview
4. Diabetic Gastroparesis Epidemiology and Patient Population
5. Diabetic Gastroparesis Epidemiology by Countries (2017-2028)
5.1. United States- Epidemiology (2017-2028)
5.2. EU-5 - Epidemiology (2017-2028)
5.3. Germany-Epidemiology (2017-2028)
5.4. France-Epidemiology (2017-2028)
5.5. Italy-Epidemiology (2017-2028)
5.6. Spain-Epidemiology (2017-2028)
5.7. United Kingdom-Epidemiology (2017-2028)
5.8. Japan-Epidemiology (2017-2028)
6. Diabetic Gastroparesis Treatments & Medical Practices
7. Diabetic Gastroparesis Emerging Therapies
7.1. Key Cross Competition
7.2. Relamorelin: Allergan
8. Diabetic Gastroparesis Market Size
9. 7MM: Country-Wise Market Analysis
9.1. United States Market Size
9.2. Germany Market Size
9.3. France Market Size
9.4. Italy Market Size
9.5. Spain Market Size
9.6. United Kingdom Market Size
9.7. Japan Market Size
10. Market Drivers
11. Market Barriers
12. Diabetic Gastroparesis Report Methodology

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Contact us:
Shruti Thakur
info@delveinsight.com
+919650213330
SOURCE DelveInsight